Fulcrum Therapeutics, Inc.
NASDAQ:FULCBiotechnology
+$0.06 today
- Market cap
- $284.14M
- Beta
- 2.92
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.00
Volume 0.63M
Average 1.78M
FULC Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Fulcrum Therapeutics, Inc.NASDAQ: FULC
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $18.89M (cash outflow) rose 7.0% year over year, behind the +14824.7% change in trailing-twelve-month net income. Sequentially, it fell 7.1% from the prior quarter. Over 3 fiscal years it compounded at -12.0% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$41.18M (-45.0%) for the fiscal year ending Dec 2026, a slowdown from the +670.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$18.89M-7.1% QoQ
- Last fiscal yearDec 2025
- -$74.88M+670.0% YoY
- LTMMar 2026
- -$76.12M+14824.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +7.0% | +13.2% | +6.2 pp |
| 1 year | +670.0% | -45.0% | -715.0 pp |
| 3-year CAGR | -12.0% | -41.1% | -29.1 pp |
| 5-year CAGR | -32.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (74.88M) USD
- Year-over-year change
- -670.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (74.88M) | -670.0% |
| FY2024 | 2024-12-31 | (9.73M) | +90.0% |
| FY2023 | 2023-12-31 | (97.34M) | +11.4% |
| FY2022 | 2022-12-31 | (109.87M) | -35.9% |
| FY2021 | 2021-12-31 | (80.85M) | — |
Net Income vs competitors
How FULC compares with its peers on the latest reported figures
- FULC's LTM Mar 2026 net income of $76.12M is the 6th largest of the 10 companies compared; the peer median is $71.67M.
- Its year-over-year change of +14824.7% is the highest of 10, against a peer median of +22.0%.
- Over three fiscal years its annual growth of -12.0% compares with a peer median of +17.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $222.39M | -13.8% | +21.9% | — |
| LTM Mar 2026 | $218.8M | +7.2% | +24.8% | 344.6% | |
| LTM Mar 2026 | $136.99M | -8.6% | -3.2% | 173.0% | |
| LTM Mar 2026 | $98.64M | +22.0% | +17.9% | — | |
| LTM Mar 2026 | $81.36M | +148.9% | -73.6% | 822.4% | |
| LTM Mar 2026 | $76.12M | +14824.7% | -12.0% | — | |
| LTM Mar 2026 | $71.67M | +24.7% | -7.9% | 1605.2% | |
| LTM Mar 2026 | $68.17M | +23.5% | +19.2% | — | |
| LTM Mar 2026 | $64.01M | +294.9% | +34.1% | 433.1% | |
| LTM Mar 2026 | $26.09M | -85.3% | -21.0% | 37.5% | |
| Peer median (excluding FULC) | $71.67M | +22.0% | +17.9% | 388.8% | |
Competitors are the stored peer set for FULC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (80.85M) | (109.87M) | (97.34M) | (9.73M) | (74.88M) |
| Depreciation & Amortization | 2.52M | 2.41M | 2.17M | 1.59M | 1.39M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.07M | 13.35M | 14.8M | 14.55M | 12.47M |
| Change in Working Capital | (11.89M) | (3.09M) | (4.61M) | (4.25M) | 3.91M |
| Accounts Receivables | (500K) | 2.5M | (308K) | (1.56M) | 2.1M |
| Inventory | 1.25M | 0 | 0 | 0 | 0 |
| Accounts Payables | 973K | (1.18M) | (853K) | (1.59M) | 428K |
| Other Working Capital | (13.61M) | (4.42M) | (3.45M) | (1.1M) | 1.39M |
| Other Non-Cash Items | 673K | 152K | (5.99M) | (4.39M) | (2.95M) |
| Operating Cash Flow | (78.48M) | (97.05M) | (90.97M) | (2.22M) | (60.07M) |
| Capital Expenditures | (1.71M) | (1.96M) | (508K) | (278K) | (314K) |
| Acquisitions (Net) | 127.96M | (14.38M) | 0 | 0 | 0 |
| Purchases of Investments | (216.23M) | (151.15M) | (194.89M) | (178.59M) | (180.22M) |
| Sales of Investments | 88.28M | 165.53M | 158.71M | 211.1M | 211.25M |
| Other Investing Activities | (127.96M) | 14.38M | 0 | 0 | 0 |
| Investing Cash Flow | (129.67M) | 12.41M | (36.69M) | 32.23M | 30.72M |
| Debt Repayment | (18K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 182.86M | 80.8M | 117.35M | 2.75M | 168.67M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.67M | 3.52M | 777K | 0 | 0 |
| Financing Cash Flow | 186.51M | 84.32M | 118.12M | 2.75M | 168.67M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (21.64M) | (314K) | (9.54M) | 32.76M | 139.32M |
| Free Cash Flow | (80.19M) | (99.01M) | (91.47M) | (2.5M) | (60.38M) |
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
Intrinsic Alpha fair value
Locked
Current Price
$3.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.